Aaron T. Gerds, MD, MS, discusses available treatment options for patients with myelofibrosis and some of the agents that are currently under development, inching toward regulatory approval in the field of myelofibrosis.
Aaron T. Gerds, MD, MS, assistant professor in Medicine (Hematology and Medical Oncology) at the Cleveland Clinic, discusses available treatment options for patients with myelofibrosis and some of the agents that are currently under development, inching toward regulatory approval in the field of myelofibrosis.
For patients with myelofibrosis, a variety of FDA-approved therapies exist. Options for patients include ruxolitinib (Jakafi), fedratinib (Inrebic), pacritinib (Vonjo), and most recently, momelotinib (Ojjaara), which was approved in September 2023 for the treatment of patients with myelofibrosis.
The international, randomized, double-blind, controlled, phase 3 MOMENTUM trial (NCT04173494) served as the basis of the FDA approval of momelotinib for this patient population. Based on recent trials, including the MOMENTUM study, momelotinib will be a key therapy for patients who have anemia and who have been previously treated with a JAK inhibitor.
In addition, Gerds explains that new therapies are being developed that will potentially allow the space to move beyond just JAK inhibitors.
Transcription:
0:10 | Well this is first of a series of randomized phase 3 trials that are being completed in myelofibrosis. I myself, and many others in the field, expect the next couple of years to be a period of rapid growth and change. We already had a new drug approved, pacritinib, [as well as] momelotinib.
0:25 | We have pelabresib [CPI-0610] coming along in phase 3 trials and navitoclax [previously ABT-263] coming along with phase 3 trials and that tell us that all of these trials should be finishing in the next year or 2 and potentially moving us, even beyond JAK inhibitors for the space. So not only would we potentially have JAK inhibitors approved to treat patients, we may have therapeutics outside of JAK inhibitors to treat these patients, which will be just kind of a massive change in the field.
Rossetti Reviews Myelofibrosis Risk Stratification and Outcome Data for Pacritinib
July 17th 2024During a Case-Based Roundtable® event, James M. Rossetti, DO, discussed the role of risk scoring and stratification tools and treatment for a patient with declining hemoglobin and platelet counts due to primary myelofibrosis.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More
Ruxolitinib Treatment in Myelofibrosis Still Effective, Regardless of Anemia
June 21st 2024New or worsening anemia did not appear to reduce the clinical benefit of ruxolitinib in myelofibrosis patients, and the median overall survival was similar between patients with and without new or worsening anemia.
Read More
Challenging Disease Features of Myelofibrosis Lead to Use of JAK Inhibitors
June 17th 2024During a Case-Based Roundtable® event, Kristen Pettit, MD, moderated a discussion on which disease features of myelofibrosis are most challenging and when to use JAK inhibitors in the first article of a 2-part series.
Read More